such as a drug and a device or a biologic and a device. These products can provide enhanced therapeutic benefits but bring complexity to the regulatory submission process. The regulatory pathway is determined primarily by the primary mode of action (PMOA) of the combination product.

1.1 Primary Mode of Action

The primary mode of action is critical in establishing which center will oversee the product’s regulatory pathway. For instance, if a drug is the PMOA, the FDA will consider it a drug product; if a device is the PMOA, it will be treated as a device for regulatory purposes. Understanding how the PMOA influences product classification can dramatically affect the development and approval process.

1.2 Example Scenarios

• A drug-coated stent is primarily intended to deliver a drug to treat coronary artery disease. Here, the stent (device) serves as the primary function of delivering the therapy, but the drug plays a critical supportive role.
• An insulin injector pen involves a device that is intended predominantly for drug delivery, thus classified under the PMOA of the drug.

2. Regulatory Pathways in the US

The FDA’s regulatory framework for combination products is outlined under 21 CFR Parts 3 and 4. The agency engages in a coordinated review process to ensure that both the drug and device aspects meet the necessary regulatory requirements. The pathways used for approval include New Drug Applications (NDA), Abbreviated New Drug Applications (ANDA), Premarket Approval Applications (PMA), and 510(k) clearances.

2.1 Submission Types

For combination products, the following submission types may be applicable:

• New Drug Application (NDA): Required when the combination product is classified under the drug category with a PMOA related to the active pharmaceutical ingredient.
• Premarket Approval (PMA): Required for high-risk devices where a combination product includes a high-risk device as its main component.
• Abbreviated New Drug Application (ANDA): Usable for generic versions of drug products combined with devices that do not alter the drug’s primary function.
• 510(k) submission: Utilized for device-related combination products where the applicant must demonstrate substantial equivalence to a predicate device.

2.2 Coordination Between OPQ and CDRH

The coordination between the Office of Pharmaceutical Quality (OPQ) and the Center for Devices and Radiological Health (CDRH) is crucial in ensuring a streamlined review process. OPQ focuses on the drug component’s quality and ensures compliance with Good Manufacturing Practices (GMP) as outlined in 21 CFR Part 210 and Part 211, while CDRH oversees device components and compliance according to 21 CFR Parts 820 and 821.

3. Regulatory Framework in the EU

The European Medicines Agency (EMA) and national authorities regulate combination products differently than the FDA. The European regulatory system categorizes these products based on their primary intended purpose, which aligns closely with the PMOA principle recognized by the FDA.

3.1 Categories of Combination Products

In the EU, combination products can be categorized as:

• Medicinal Product/Device: A product that offers a medical benefit combined with a delivery device.
• Biologic Product/Device: Similar to the medicinal product/device, this involves biologics that are delivered via devices.

3.2 European Submission Processes

Applications for combination products in the EU may require adherence to multiple directives, including the Medical Devices Regulation (MDR) and the In-vitro Diagnostic Devices Regulation (IVDR), depending on the regulatory classification of the device component.

4. Good Manufacturing Practices (GMP) in Combination Products

GMP requirements are essential for the successful development and commercialization of combination products. In the US, 21 CFR Part 210 and Part 211 outline the necessary practices for drugs, while Part 820 provides the expectations for device manufacturing. Similarly, in the EU, compliance with the EU GMP guidelines ensures that combined manufacturing practices align with both drug and device standards.

4.1 Importance of Combination GMP

Implementation of combination GMP practices ensures:

• Quality assurance across product development stages, minimizing variability.
• Streamlined compliance with both FDA and EMA regulations.
• Enhanced post-market safety through vigilant monitoring and quality controls.

4.2 Challenges in Establishing GMP

Companies often face challenges due to differing standards and guidelines between jurisdictions. Therefore, a robust risk management approach is necessary to address these discrepancies throughout product development.

5. Post-Market Safety Considerations

Post-market safety is vital in ensuring that combination products continue to meet safety and effectiveness standards post-approval. In the US, 21 CFR Part 803 outlines the requirements for Medical Device Reporting, emphasizing the need for reporting device-related adverse events.

5.1 Risk Management Post-Approval

Implementing comprehensive post-market surveillance, risk management strategies, and vigilance programs safeguards patient safety and ensures regulatory compliance.

5.2 European Post-Market Surveillance Activities

In the EU, manufacturers are required to perform continuous post-market surveillance and prepare periodic safety update reports (PSURs) to address the ongoing safety of combination products.

6. Key Considerations for Platform Devices

Platform devices are multi-function systems capable of delivering various drug formulations or biologic agents. These products present unique regulatory challenges, particularly in defining their primary mode of action and establishing appropriate pathways for approval.

6.1 Regulatory Strategy for Platform Devices

• Develop a clear regulatory strategy based on intended uses and functionalities of the platform.
• Consider modular submissions to streamline the review process when presenting multiple indications.

6.2 Coordination Efforts

Establishing coordination efforts with various regulatory bodies ensures that approvals for new applications are handled efficiently, without compromising on safety and quality.

Conclusion

In summary, the successful navigation of the regulatory landscape governing combination products requires an intricate understanding of regulatory requirements across multiple jurisdictions. By comprehending the implications of primary mode of action, the coordination between OPQ and CDRH, and adhering to manufacturing and post-market safety guidelines, professionals can facilitate streamlined pathways for compliance. Through diligent planning and strategic insights, regulatory, quality, clinical, and RA/QA teams can ensure that combination products meet both FDA and EU standards, ultimately safeguarding public health.